Developer docs
API playgroundTry for free, no card

Search company profiles

Noze

Full company profile

uuid0000xh6

Namestring
Noze
Legal namestring
Noze Inc.
Websiteurl
noze.ca
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Noze is a Montreal-based medical technology company developing an AI-powered digital olfaction platform for non-invasive, breath-based disease detection. The company's flagship product, the DiagNoze breathalyzer, combines nano-sensor arrays ("Smell on Silicon") derived from exclusively licensed NASA patents with a proprietary AI Perception Engine that translates volatile organic compound (VOC) patterns in exhaled breath into diagnostic outputs. The platform operates in two modes: SpotLight, which isolates a single known biomarker for rapid point-of-care triage, and DeepScan, which scans for disease-specific molecular fingerprints across multiple conditions.

The company's intended applications span five clinical verticals: oncology (breast and lung cancer detection), infectious diseases (tuberculosis and malaria screening in high-burden countries), metabolic health monitoring, critical care triage, and asthma/respiratory disease management. Clinical validation reported in peer-reviewed publications includes 85.4% accuracy for non-small cell lung cancer detection in a 158-patient study and 85-100% accuracy for breast cancer detection across stages in a 5,047-woman study. The Bill & Melinda Gates Foundation has provided $6.8 million in grants across three awards (March 2023, March 2024, July 2024) to support infectious disease applications, while the company has separately raised $24.4 million CAD from equity investors including TandemLaunch, Mistral Venture Partners, Fonds Innovexport, and Creative Destruction Labs.

Noze is a pre-revenue company: the DiagNoze device is under development, has not received FDA approval or clearance from any health authority, and is not commercially available. The company is pursuing FDA Breakthrough Device designation and targeting commercial launch by early 2026, with a Series B funding round targeting a $30 million USD minimum to support clinical trials. Revenue is expected to flow through hardware sales of the diagnostic device to healthcare providers, with initial geographic focus on high-burden countries for infectious disease screening via Gates Foundation-supported distribution. The company was founded in 2015 as Stratuscent, rebranded to Noze in 2023, and is led by CEO Karim Aly (MBA) and Founder/CTO Ashok Masilamani (PhD).

Short descriptiontext

Noze is a Montreal-based medical technology company developing an AI-powered breathalyzer (DiagNoze) that uses nano-sensor arrays and proprietary neural models to detect diseases non-invasively across oncology, infectious disease, metabolic, and respiratory applications for healthcare providers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breath diagnostics, digital olfaction, medical breathalyzer, nano-sensor arrays, non-invasive diagnostics
Industry3 codes
PRIMARYHLAKANAC
Pulmonary Function Testing (PFT) & Respiratory Diagnostics
SECONDARYEUAHACAK
Odor Monitoring & Olfactometry
Energy, Utilities & Environment/Environmental Compliance, Monitoring & Consulting/Environmental Monitoring & Sampling (Air/Water/Soil/Noise)
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Medical Diagnostic Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Diagnostic Devices
TypeHardware Sales
Description

The company is developing breath-based diagnostic devices (DiagNoze) for clinical use. The device is currently under development and has not received FDA approval or any regulatory clearance. Revenue will be generated through device sales to healthcare providers once regulatory approvals are obtained.

noze.ca
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1DiagNoze
Description

Medical breathalyzer device for tuberculosis detection and infectious disease screening

noze.ca
+2 more records
Core offering1 text field

Noze develops an AI-powered digital olfaction platform that combines nano-sensor arrays (Smell on Silicon) with proprietary neural models (AI Perception Engine) to detect disease biomarkers in exhaled breath. The flagship DiagNoze® portable breathalyzer uses two operating modes — SpotLight™ for single-biomarker detection and DeepScan™ for multi-condition scanning — to support non-invasive screening for infectious diseases, cancer, metabolic, critical care, and respiratory conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • VOC biomarker panel detected non-small cell lung cancer with 85.4% accuracy in 2022 study of 158 patients
+1 more record
Product overview1 text field

Noze offers a unified breath-based diagnostic platform centered on the DiagNoze® device. The platform combines SpotLight™ (single biomarker rapid detection) and DeepScan™ (comprehensive disease fingerprint scanning) modes, powered by the proprietary AI Perception Engine and Smell on Silicon nano-sensor technology. Originally developed from NASA-licensed patents, the system analyzes volatile organic compounds in breath for disease detection across oncology, infectious diseases (tuberculosis, malaria), metabolic health, critical care, and respiratory conditions. The device is under development and not yet approved by FDA or any regulatory body.

Product and service1 record
1DiagNoze®
CategoryMedical Diagnostic Devices
Description

A portable, handheld breath-based diagnostic device that uses nano-sensor arrays and proprietary AI to detect volatile organic compound biomarkers in exhaled breath for rapid, non-invasive screening of infectious diseases (e.g., tuberculosis, malaria), cancer signals, metabolic conditions, and respiratory conditions at the point of care. Targeted at hospitals, clinics, and point-of-care settings in both developed and high-burden countries.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Partnership for 'Paradigm Shift in the Conduct of Clinical Trials' project. Noze is part of a consortium developing virtual clinical trial models combining innovative technologies. MHI received $9.35M from Quebec's Ministry of Economy and Innovation and $12.3M from private partners for this project.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based developer of the Breath Biopsy platform for non-invasive breath-based diagnostics across cancer, inflammatory and infectious disease. Most directly comparable competitor to Noze, addressing overlapping indications (lung cancer, infectious disease) with a similar VOC + AI approach.

TypeDirect peer
Description

US company developing ultra-sensitive breath analyzers for disease detection (and workplace cannabis testing). Comparable handheld breath-sensor product targeting point-of-care clinical diagnostics.

3Aerodiagnostics
TypeDirect peer
Description

Developer of exhaled breath analysis tools for inflammatory lung disease in pediatric and adult populations. Directly comparable breath-based diagnostic technology serving respiratory specialists.

4CMI Health (formerly Spirosure)
TypeEmerging player
Description

Maker of FeNObreath exhaled nitric oxide devices for asthma and respiratory monitoring. Comparable handheld point-of-care breath diagnostics targeting clinicians in adjacent respiratory use cases.

TypeEmerging player
Description

Commercial-stage medical device company focused on inhaled nitric oxide for respiratory infections and lung conditions. Comparable portable respiratory diagnostic/therapeutic device company addressing pulmonary indications.

TypeBroad incumbent
Description

US-based commercial lung diagnostics company with blood-based and proteomic tests for lung nodule management and infectious disease. Comparable in serving pulmonologists/oncologists with non-invasive diagnostic tests, though using blood rather than breath.

TypeBroad incumbent
Description

Ultra-sensitive biomarker detection platform used in neurology, oncology, and infectious disease research and diagnostics. Comparable in pursuing biomarker-driven, AI-enabled disease detection, though based on blood-based Simoa technology rather than breath.

TypeBroad incumbent
Description

Large molecular diagnostics and women's health company with significant breast cancer screening franchise. Relevant incumbent in oncology diagnostics that Noze's breast-cancer breath test would compete with on workflow and cost.

9Abbott Diagnostics
TypeBroad incumbent
Description

Global diagnostics giant with point-of-care, immunoassay, and molecular testing platforms across infectious disease, metabolic, and oncology. Most likely strategic acquirer and competitor across multiple Noze target indications.

10Tempus AI
TypeBroad incumbent
Description

AI-driven precision medicine company combining multi-modal data (molecular, clinical, imaging) for oncology and other diseases. Comparable in using AI to translate complex molecular signals into diagnostic/therapeutic insight, though platform-centric rather than device-centric.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Noze

Medical Diagnostic Devicesnoze.ca

Noze is a Montreal-based medical technology company developing an AI-powered breathalyzer (DiagNoze) that uses nano-sensor arrays and proprietary neural models to detect diseases non-invasively across oncology, infectious disease, metabolic, and respiratory applications for healthcare providers globally.

What Noze does

Noze is a Montreal-based medical technology company developing an AI-powered digital olfaction platform for non-invasive, breath-based disease detection. The company's flagship product, the DiagNoze breathalyzer, combines nano-sensor arrays ("Smell on Silicon") derived from exclusively licensed NASA patents with a proprietary AI Perception Engine that translates volatile organic compound (VOC) patterns in exhaled breath into diagnostic outputs. The platform operates in two modes: SpotLight, which isolates a single known biomarker for rapid point-of-care triage, and DeepScan, which scans for disease-specific molecular fingerprints across multiple conditions.

The company's intended applications span five clinical verticals: oncology (breast and lung cancer detection), infectious diseases (tuberculosis and malaria screening in high-burden countries), metabolic health monitoring, critical care triage, and asthma/respiratory disease management. Clinical validation reported in peer-reviewed publications includes 85.4% accuracy for non-small cell lung cancer detection in a 158-patient study and 85-100% accuracy for breast cancer detection across stages in a 5,047-woman study. The Bill & Melinda Gates Foundation has provided $6.8 million in grants across three awards (March 2023, March 2024, July 2024) to support infectious disease applications, while the company has separately raised $24.4 million CAD from equity investors including TandemLaunch, Mistral Venture Partners, Fonds Innovexport, and Creative Destruction Labs.

Noze is a pre-revenue company: the DiagNoze device is under development, has not received FDA approval or clearance from any health authority, and is not commercially available. The company is pursuing FDA Breakthrough Device designation and targeting commercial launch by early 2026, with a Series B funding round targeting a $30 million USD minimum to support clinical trials. Revenue is expected to flow through hardware sales of the diagnostic device to healthcare providers, with initial geographic focus on high-burden countries for infectious disease screening via Gates Foundation-supported distribution. The company was founded in 2015 as Stratuscent, rebranded to Noze in 2023, and is led by CEO Karim Aly (MBA) and Founder/CTO Ashok Masilamani (PhD).

Noze firmographics

Firmographics
Name
Noze
Legal name
Noze Inc.
Website
https://noze.ca
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Noze is a Montreal-based medical technology company developing an AI-powered breathalyzer (DiagNoze) that uses nano-sensor arrays and proprietary neural models to detect diseases non-invasively across oncology, infectious disease, metabolic, and respiratory applications for healthcare providers globally.
Ownership category
akta.pro rank

Noze industry classification

Industry
Product category
Medical Diagnostic Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAKANAC
Pulmonary Function Testing (PFT) & Respiratory Diagnostics
SECONDARYEUAHACAK
Odor Monitoring & Olfactometry
Energy, Utilities & Environment/Environmental Compliance, Monitoring & Consulting/Environmental Monitoring & Sampling (Air/Water/Soil/Noise)
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

  • Breath diagnostics
  • Digital olfaction
  • Medical breathalyzer
  • Nano-sensor arrays
  • Non-invasive diagnostics

Where Noze is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Noze business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Medical Diagnostic Devices: The company is developing breath-based diagnostic devices (DiagNoze) for clinical use. The device is currently under development and has not received FDA approval or any regulatory clearance. Revenue will be generated through device sales to healthcare providers once regulatory approvals are obtained.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Noze product offering

Product offering

Core offering

Noze develops an AI-powered digital olfaction platform that combines nano-sensor arrays (Smell on Silicon) with proprietary neural models (AI Perception Engine) to detect disease biomarkers in exhaled breath. The flagship DiagNoze® portable breathalyzer uses two operating modes — SpotLight™ for single-biomarker detection and DeepScan™ for multi-condition scanning — to support non-invasive screening for infectious diseases, cancer, metabolic, critical care, and respiratory conditions.

Product overview

Noze offers a unified breath-based diagnostic platform centered on the DiagNoze® device. The platform combines SpotLight™ (single biomarker rapid detection) and DeepScan™ (comprehensive disease fingerprint scanning) modes, powered by the proprietary AI Perception Engine and Smell on Silicon nano-sensor technology. Originally developed from NASA-licensed patents, the system analyzes volatile organic compounds in breath for disease detection across oncology, infectious diseases (tuberculosis, malaria), metabolic health, critical care, and respiratory conditions. The device is under development and not yet approved by FDA or any regulatory body.

Differentiator

Problem solved

Functional benefit

Brands

  • DiagNoze: Medical breathalyzer device for tuberculosis detection and infectious disease screening
  • SpotLight
  • DeepScan

Products and services

  • DiagNoze® A portable, handheld breath-based diagnostic device that uses nano-sensor arrays and proprietary AI to detect volatile organic compound biomarkers in exhaled breath for rapid, non-invasive screening of infectious diseases (e.g., tuberculosis, malaria), cancer signals, metabolic conditions, and respiratory conditions at the point of care. Targeted at hospitals, clinics, and point-of-care settings in both developed and high-burden countries.

Quantifiable outcome

  • VOC biomarker panel detected non-small cell lung cancer with 85.4% accuracy in 2022 study of 158 patients
  • +1 more outcomes

Companies that use Noze

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Noze technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature5 records

Noze partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Montreal Heart Institute (MHI)coreStrategic or Co-development Partner · 1 January 2021Partnership for 'Paradigm Shift in the Conduct of Clinical Trials' project. Noze is part of a consortium developing virtual clinical trial models combining innovative technologies. MHI received $9.35M from Quebec's Ministry of Economy and Innovation and $12.3M from private partners for this project.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Noze competitors and assessment

Company assessment

Direct peers

  • Owlstone Medical: UK-based developer of the Breath Biopsy platform for non-invasive breath-based diagnostics across cancer, inflammatory and infectious disease. Most directly comparable competitor to Noze, addressing overlapping indications (lung cancer, infectious disease) with a similar VOC + AI approach.
  • Hound Labs: US company developing ultra-sensitive breath analyzers for disease detection (and workplace cannabis testing). Comparable handheld breath-sensor product targeting point-of-care clinical diagnostics.
  • Aerodiagnostics: Developer of exhaled breath analysis tools for inflammatory lung disease in pediatric and adult populations. Directly comparable breath-based diagnostic technology serving respiratory specialists.

Emerging players

  • CMI Health (formerly Spirosure): Maker of FeNObreath exhaled nitric oxide devices for asthma and respiratory monitoring. Comparable handheld point-of-care breath diagnostics targeting clinicians in adjacent respiratory use cases.
  • Beyond Air: Commercial-stage medical device company focused on inhaled nitric oxide for respiratory infections and lung conditions. Comparable portable respiratory diagnostic/therapeutic device company addressing pulmonary indications.

Broad incumbents

  • Biodesix: US-based commercial lung diagnostics company with blood-based and proteomic tests for lung nodule management and infectious disease. Comparable in serving pulmonologists/oncologists with non-invasive diagnostic tests, though using blood rather than breath.
  • Quanterix: Ultra-sensitive biomarker detection platform used in neurology, oncology, and infectious disease research and diagnostics. Comparable in pursuing biomarker-driven, AI-enabled disease detection, though based on blood-based Simoa technology rather than breath.
  • Hologic: Large molecular diagnostics and women's health company with significant breast cancer screening franchise. Relevant incumbent in oncology diagnostics that Noze's breast-cancer breath test would compete with on workflow and cost.
  • Abbott Diagnostics: Global diagnostics giant with point-of-care, immunoassay, and molecular testing platforms across infectious disease, metabolic, and oncology. Most likely strategic acquirer and competitor across multiple Noze target indications.
  • Tempus AI: AI-driven precision medicine company combining multi-modal data (molecular, clinical, imaging) for oncology and other diseases. Comparable in using AI to translate complex molecular signals into diagnostic/therapeutic insight, though platform-centric rather than device-centric.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Noze social profiles

Digital presence

Noze compliance and trust

Trust signal

Compliance2 records

Noze financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Noze leadership team

Management profile

Number of profiles

Profiles9 records

Noze funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Noze M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Noze

What does Noze do?

Noze develops an AI-powered digital olfaction platform that combines nano-sensor arrays (Smell on Silicon) with proprietary neural models (AI Perception Engine) to detect disease biomarkers in exhaled breath. The flagship DiagNoze® portable breathalyzer uses two operating modes — SpotLight™ for single-biomarker detection and DeepScan™ for multi-condition scanning — to support non-invasive screening for infectious diseases, cancer, metabolic, critical care, and respiratory conditions.

Is Noze a public or private company?

Noze is a private company. It is classified as venture growth investor backed and is currently operating.

When was Noze founded?

Noze was founded in 2015. It employs 11 to 50 people.

Where is Noze based?

Noze is headquartered in Montreal, Canada, in the North America region.

How does Noze make money?

One revenue line is on record: medical Diagnostic Devices.

Who are Noze's main competitors?

Direct peers on record are Owlstone Medical, Hound Labs and Aerodiagnostics. Emerging players are CMI Health (formerly Spirosure) and Beyond Air. Broad incumbents are Biodesix, Quanterix, Hologic, Abbott Diagnostics and Tempus AI.

Does Noze have an API?

No public API is recorded for Noze.

What industry is Noze in?

Noze's product category is Medical Diagnostic Devices. Its primary akta.pro industry code is HLAKANAC, Pulmonary Function Testing (PFT) & Respiratory Diagnostics, with a secondary code of EUAHACAK, Odor Monitoring & Olfactometry. Its NAICS code is 334510 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
RTE.ieHow new technology could change how we detect breast cancerNew breast cancer detection technologies including an at-home wearable patch by Feminai and a breath test by Canadian company Noze are in development and early clinical trials, offering potential solutions for the roughly 50% of women with dense breasts whom standard mammograms often fail. Ireland's national breast screening programme faces significant gaps, including age restrictions covering only women 50-69, delayed appointments, and no mandatory breast density notification unlike the US. Research by Dr. Iseult Browne at The Royal Marsden Hospital shows that blood tests measuring circulating tumour DNA could enable doctors to determine within four weeks whether breast cancer treatment is working.ConstantiainstituteSmells good? Here's how AI and IoT are driving digital scent technologyArtificial Intelligence and the Internet of Things are significantly expanding the applications of digital scent technology across various industries. Key developments include AI-driven odor recognition, disease detection systems like those by NoZe, and IoT-enabled smart diffusers from companies such as Inhalio and ScentBridge.FinSMEsNoze Secures $5M Equity Investment from Bill & Melinda Gates FoundationNoze, a Montreal-based breath diagnostics company, secured a $5M equity investment from the Bill & Melinda Gates Foundation, bringing total funding to $6.8M. The funds will support development of its disease detection platform for low- and middle-income countries. The company's handheld breathalyzer, DiagNoze, detects disease biomarkers without blood draws or lab equipment.PR NewswireNew Funding Announced for Revolutionary Disease Detection TechnologyNoze, a Canadian breath-based diagnostics startup, received a $5 million equity investment from the Bill & Melinda Gates Foundation, its first Canadian equity investment. The funding brings total Gates contributions to $6.8 million and will support development of its DiagNoze device for low- and middle-income countries, targeting diseases like tuberculosis.TmcnetCanadian MedTech Startup Amplifies Fight Against Tuberculosis with New GrantCanadian medtech startup Noze received a new grant from the Bill & Melinda Gates Foundation, bringing total funding to $1.8 million. The grant will fund a clinical study using its DiagNoze breathalyzer to detect tuberculosis in high-burden countries. The study is expected to begin in fall 2024.BioSpaceCanadian MedTech Startup Amplifies Fight Against Tuberculosis with New GrantCanadian MedTech startup Noze announced it received a new grant from the Bill & Melinda Gates Foundation, bringing total funding to $1.8 million. The funds will support a clinical study for DiagNoze®, a handheld breathalyzer designed to detect tuberculosis in high-burden countries. The study is expected to begin in the fall of 2024.PR NewswireCanadian MedTech Startup Amplifies Fight Against Tuberculosis with New GrantCanadian MedTech startup Noze received a new grant from the Bill & Melinda Gates Foundation, bringing its total funding to $1.8 million to support tuberculosis diagnostics. The funding will finance a clinical study using Noze's DiagNoze® handheld breathalyzer to detect TB in high-burden countries, with the study expected to begin in fall 2024. This initiative aims to improve patient outcomes by enabling rapid, cost-effective screening in underserved regions.BenzingaBill Gates's March Venture Investments: Biotech, Energy, And Taking On Methane EmissionsBill Gates made multiple venture investments in March across biotech and clean energy sectors through his personal portfolio and Breakthrough Energy Ventures, the investment arm of the Bill and Melinda Gates Foundation. The biotech investments include SpyBiotech (vaccine development), DelSiTech (nanoparticle drug delivery), Noze (disease-detecting digital nose technology), and Zoetis (livestock medicine and methane reduction). The energy investments through Breakthrough Energy Ventures include Stratus Materials (lithium-ion battery materials), ClearFlame Engine Technologies (ethanol fuel solutions for diesel engines), and Viridos (algae-based biofuels for aviation and maritime transport).BetaKitT: The Healthtech Times – Haply building Surgeon Simulator backed by BDC Deep TechMontréal-based Haply Robotics secured $4.8 million CAD in seed funding led by BDC Capital’s Deep Tech Venture Fund to develop haptic technology for medical training. Additionally, Artera raised $90 million to distribute its AI-powered prostate cancer test globally, while Noze received a $1 million grant from the Gates Foundation to build a breathalyzer for detecting infectious diseases.